Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
J.C. Penney asked to have the weekend to complete details of it bankruptcy exit and sale
Knight Ridder/Tribune 12:09 PM ET 10/16/2020
J.C. Penney (JCPNQ) told the bankruptcy court Friday that it will miss its deadline to file documents that outline its reorganization and sale and it expects to make the disclosures on Monday.
A hearing is scheduled for Tuesday and negotiations that have been underway for months are expected to be completed by then, according to the motion filed to extend the deadline to Monday.
ALYI Explores EV Battery Solutions with Samsung SDI and Gegadyne Energy
Dallas, Texas--(Newsfile Corp. - September 14, 2020) - Alternet Systems, Inc. (OTC:ALYI) today announced that in addition to its own groundbreaking electric vehicle (EV) battery innovation progress, the Company is exploring solutions with Samsung SDI and Gegadyne Energy that management anticipates could generate an independent stream of revenue adding to the company's current $300 million in projected electric vehicle revenue.
ALYI Announces LOI For New EV Fleet Order - Revenue Outlook Anticipated To Increase To $500 Million
PR NEWSWIRE 10:56 AM ET 9/11/2020
Update...see below:
PHOENIX, Sept. 11, 2019 /PRNewswire/ -- Creative Medical Technology Holdings (OTC-CELZ) reported today it has signed an agreement with Edge Media Network to introduce CaverStem® to their community in an integrated campaign spanning web, email, social media, and in-person events.
CELZ data released. Primary endpoint met! Please see correct information below:
Phoenix, AZ September 4, 2019 Creative Medical Technology Holdings (OTC-CELZ) reported today completion of data analysis and submission of a research paper describing a total of 140 patients treated with the CaverStem® procedure. The patients suffered from erectile dysfunction for whom standard drug interventions such as Cialis, Levitra, and Viagra (PDE-5) were ineffective.
The data analysis demonstrated that primary end-point of the study was met.
“It is very exciting to see the patented cell based intervention that we first described in peer reviewed literature in our 2013 publication1 has now grown to become a commercialized procedure, available through qualified physicians, after completing a clinical trial with independent monitoring and oversight for safety and efficacy,” said Amit Patel, MD, MS, Board Member of the Company.
In the submitted paper, a total of 40 patients were treated in the primary trial and 100 in the clinical registry. This signifies one of the largest clinical studies of a non-drug treatment for erectile dysfunction.
“The current data is derived from cells that are extracted from the same patient that they are to be used on, and that the cells are not chemically or biologically manipulated. The devices used for extraction and concentration of the cells are FDA cleared. This approach is completely different from unethical and potentially dangerous approaches other groups are using including non-matched stem cells or fat derived stem cells using “home-made” isolation protocols.”
“Since founding the company and acquisition of the technology, through patent prosecution to engaging in the clinical trials and now in the treatment of patients in multiple locations, we have maintained an ongoing positive outlook for our CaverStem® technology. The results which will be published in a peer-reviewed journal as well as reflected on clinicaltrials.gov substantiate our long term belief in the potential safety and efficacy of our technology,” said Timothy Warbington, President and CEO of Creative Medical Technology Holdings, Inc. “We are glad to be offering this breakthrough treatment to patients with erectile dysfunction who currently have no other options as part of the ongoing clinical registry.”
To learn more, please visit www.caverstem.com
About Erectile Dysfunction
Erectile dysfunction (ED) is characterized by the lack of ability to achieve and maintain penile erection for intercourse. Methods used to quantify ED include the Erectile Function Visual Analog Scale (EF-VAS) and the International Index of Erectile Function (IIEF-5), however clinically it is primarily diagnosed based on symptomology. In our aging society, ED is becoming an increasing problem. According to one study 39% of men at age 40 experience symptoms of ED, whereas by age 70 the incidence rises to 67%. In this latter age group, it is believed that 50-85% of ED cases are associated with hypertension, diabetes, cardiovascular disease and dyslipidemia. Overall, it is estimated that 10-30 million Americans suffer from this condition.
Data (8K) released! Endpoint met! See information below!
Phoenix, AZ September 4, 2019 Creative Medical Technology Holdings (OTC-CELZ) reported today completion of data analysis and submission of a research paper describing a total of 140 patients treated with the CaverStem® procedure. The patients suffered from erectile dysfunction for whom standard drug interventions such as Cialis, Levitra, and Viagra (PDE-5) were ineffective.
The data analysis demonstrated that primary end-point of the study was met.
“It is very exciting to see the patented cell based intervention that we first described in peer reviewed literature in our 2013 publication1 has now grown to become a commercialized procedure, available through qualified physicians, after completing a clinical trial with independent monitoring and oversight for safety and efficacy,” said Amit Patel, MD, MS, Board Member of the Company.
In the submitted paper, a total of 40 patients were treated in the primary trial and 100 in the clinical registry. This signifies one of the largest clinical studies of a non-drug treatment for erectile dysfunction.
“The current data is derived from cells that are extracted from the same patient that they are to be used on, and that the cells are not chemically or biologically manipulated. The devices used for extraction and concentration of the cells are FDA cleared. This approach is completely different from unethical and potentially dangerous approaches other groups are using including non-matched stem cells or fat derived stem cells using “home-made” isolation protocols.”
“Since founding the company and acquisition of the technology, through patent prosecution to engaging in the clinical trials and now in the treatment of patients in multiple locations, we have maintained an ongoing positive outlook for our CaverStem® technology. The results which will be published in a peer-reviewed journal as well as reflected on clinicaltrials.gov substantiate our long term belief in the potential safety and efficacy of our technology,” said Timothy Warbington, President and CEO of Creative Medical Technology Holdings, Inc. “We are glad to be offering this breakthrough treatment to patients with erectile dysfunction who currently have no other options as part of the ongoing clinical registry.”
To learn more, please visit www.caverstem.com
About Erectile Dysfunction
Erectile dysfunction (ED) is characterized by the lack of ability to achieve and maintain penile erection for intercourse. Methods used to quantify ED include the Erectile Function Visual Analog Scale (EF-VAS) and the International Index of Erectile Function (IIEF-5), however clinically it is primarily diagnosed based on symptomology. In our aging society, ED is becoming an increasing problem. According to one study 39% of men at age 40 experience symptoms of ED, whereas by age 70 the incidence rises to 67%. In this latter age group, it is believed that 50-85% of ED cases are associated with hypertension, diabetes, cardiovascular disease and dyslipidemia. Overall, it is estimated that 10-30 million Americans suffer from this condition.
Fox News currently broadcasting President Trump discussing the Farm Bill.
Farm Bill signed by President Trump!
Insider buy from Director on 10/17/18 (Form 4). Timothy Warbington - 4.4 million shares. Form SC 13D/A on 10/17/18.
Hi. Anyone have a an idea why it was halted?
10Q has just been released. Thoughts?
13 million shares were acquired on Aug. 3 by Greg Halpern (Charmain/CFO).
There are no guarantees when investing in start-ups. However, the risk with this stock is minimized based on the current (advantageous) entry price. MAXD has enough pending catalysts to offer great upside. At worse, I'm out a few hundred dollars. At best, I'm up a few thousand dollars. It's important to understand why you invest...it'll keep you on solid footing and clear your mind of all the white noise from those who wish to distract.
Comic Con starts today. Halpern previously mentioned that a business update would be communicated around the event date. Could see news today...
Closed in 4's for the first time in days. Trending up? Possible.
The current share price is near the PPS where the huge run occurred in March.
Halpern (CEO) just purchased 11,095,461 shares per latest Form 4 released today (after hours).